DK2252301T3 - USE OF ulipristal TREATMENT Uterine Fibroids - Google Patents

USE OF ulipristal TREATMENT Uterine Fibroids Download PDF

Info

Publication number
DK2252301T3
DK2252301T3 DK09706347.3T DK09706347T DK2252301T3 DK 2252301 T3 DK2252301 T3 DK 2252301T3 DK 09706347 T DK09706347 T DK 09706347T DK 2252301 T3 DK2252301 T3 DK 2252301T3
Authority
DK
Denmark
Prior art keywords
cdb
fibroids
uterus
ulipristal
ulipristal acetate
Prior art date
Application number
DK09706347.3T
Other languages
Danish (da)
English (en)
Inventor
Erin Gainer
Andre Ulmann
Diana Blithe
Lynnette Nieman
Original Assignee
Us Health
Hra Pharma Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40551565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2252301(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Health, Hra Pharma Lab filed Critical Us Health
Application granted granted Critical
Publication of DK2252301T3 publication Critical patent/DK2252301T3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
DK09706347.3T 2008-01-29 2009-01-28 USE OF ulipristal TREATMENT Uterine Fibroids DK2252301T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/021,610 US8299050B2 (en) 2008-01-29 2008-01-29 Method for treating uterine fibroids
PCT/EP2009/050961 WO2009095418A1 (en) 2008-01-29 2009-01-28 Use of ulipristal for treating uterine fibroids

Publications (1)

Publication Number Publication Date
DK2252301T3 true DK2252301T3 (en) 2014-02-17

Family

ID=40551565

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09706347.3T DK2252301T3 (en) 2008-01-29 2009-01-28 USE OF ulipristal TREATMENT Uterine Fibroids

Country Status (20)

Country Link
US (5) US8299050B2 (https=)
EP (2) EP2252301B1 (https=)
JP (2) JP5906016B2 (https=)
KR (2) KR101571400B1 (https=)
AU (1) AU2009209652B2 (https=)
BR (1) BRPI0907028B8 (https=)
CA (2) CA2713254C (https=)
CY (1) CY1116485T1 (https=)
DK (1) DK2252301T3 (https=)
ES (1) ES2450592T3 (https=)
HR (1) HRP20140132T1 (https=)
IL (2) IL207182A (https=)
MX (1) MX2010008270A (https=)
NZ (1) NZ587439A (https=)
PL (1) PL2252301T3 (https=)
PT (1) PT2252301E (https=)
SI (1) SI2252301T1 (https=)
TW (1) TWI445537B (https=)
WO (1) WO2009095418A1 (https=)
ZA (1) ZA201006049B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
EP3865502A1 (en) * 2010-03-22 2021-08-18 Allergan Pharmaceuticals International Limited Compositions and methods for non-toxic delivery of cdb-2914
EP2471537A1 (en) * 2010-12-30 2012-07-04 PregLem S.A. Treatment of pain associated with dislocation of basal endometrium
EP2545922A1 (en) * 2011-07-12 2013-01-16 PregLem S.A. Treatment of excessive menstrual bleeding associated with uterine fibroids
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
WO2014050105A1 (en) * 2012-09-28 2014-04-03 Aska Pharmaceutical Co., Ltd. Amorphous ulipristal acetate
FR2997628B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant un modulateur selectif des recepteurs a la progesterone
FR2997627B1 (fr) * 2012-11-08 2015-01-16 Hra Pharma Lab Produit de co-micronisation comprenant de l'ulipristal acetate
HK1213487A1 (zh) * 2012-12-14 2016-07-08 The Population Council, Inc. 銅子宮環
CN103006595B (zh) * 2012-12-25 2018-04-06 江苏亚邦爱普森药业有限公司 制备醋酸优力司特片的方法
JP6255038B2 (ja) * 2013-02-26 2017-12-27 トリアクト セラピューティクス，インク． 癌治療
HK1221169A1 (zh) * 2013-04-10 2017-05-26 Preglem S.A. 孕酮受体调节剂在子宫肌瘤疗法中的用途
US10444958B2 (en) * 2013-09-23 2019-10-15 Adobe Systems Incorporated Visual example-based user interface for adjusting photos along two dimensions
US10238722B2 (en) 2014-11-24 2019-03-26 Ramot At Tel-Aviv University Ltd. Pigment epithelium derived factor (PEDF) for the treatment of uterine fibroids
WO2017216637A2 (en) 2017-08-04 2017-12-21 Alvogen Malta Operations (Row) Ltd Tablet form including ulipristal acetate and the methods for its preparation
KR102086827B1 (ko) * 2017-12-14 2020-03-10 경희대학교 산학협력단 자궁근육종 치료용 울리프리스탈 아세테이트
KR102043349B1 (ko) * 2018-01-10 2019-11-12 경희대학교 산학협력단 대장암 치료 용도의 울리프리스탈 아세테이트
AU2021225117A1 (en) 2020-02-19 2022-10-06 Vélfag ehf. Device and method for filleting and pin-bone removal

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
US5468741A (en) * 1993-05-28 1995-11-21 The Regents Of The University Of California Use of low levels of mifepristone to treat leiomyomata
DE4426601A1 (de) * 1994-07-27 1996-02-01 Schering Ag Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
UA37259C2 (uk) * 1995-02-02 2001-05-15 Шерінг Актієнгезеллшафт Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
WO1997041145A1 (en) 1996-05-01 1997-11-06 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
NZ504351A (en) * 1997-11-14 2002-10-25 Akzo Nobel Nv Contraceptive kit comprising progestogen and anti-progestogen and use in treating bleeding induced by a progestogen-only contraceptive regimen
US6262042B1 (en) * 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) * 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
CA2516319C (en) 2003-02-28 2012-09-18 The Government Of The United States Of America, As Represented By The Se Cretary, Department Of Health And Human Services Method for preparing 17.alpha.-acetoxy-11.beta.-(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, intermediates thereof, and methods for the preparation of such intermediates
CA2573266C (en) 2004-07-09 2011-11-08 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
US20060251581A1 (en) * 2005-05-09 2006-11-09 Mcintyre Jon T Method for treatment of uterine fibroid tumors
WO2007038796A1 (en) 2005-09-29 2007-04-05 Repros Therapeutics Inc. Formulations with improved bioavailability, comprising a steroid derivative and a polyglycolysed glyceride
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
EP2094275A2 (en) * 2006-12-28 2009-09-02 Repros Therapeutics Inc. Methods and formulations for improved bioavailability of antiprogestins
SI2148681T1 (sl) 2007-04-20 2016-07-29 Preglem S.A. Selektivni modulatorji progesterona v zdravljenju maternične krvavitve
US8299050B2 (en) 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
CA2857798A1 (en) 2009-09-06
US8299050B2 (en) 2012-10-30
IL207182A0 (en) 2010-12-30
EP2252301B1 (en) 2013-12-11
JP2015120711A (ja) 2015-07-02
WO2009095418A1 (en) 2009-08-06
US9682088B2 (en) 2017-06-20
JP6138838B2 (ja) 2017-05-31
US20170246189A1 (en) 2017-08-31
BRPI0907028B1 (pt) 2019-09-24
NZ587439A (en) 2012-06-29
EP2684565B1 (en) 2019-10-02
US20130023506A1 (en) 2013-01-24
KR101571400B1 (ko) 2015-11-24
MX2010008270A (es) 2011-01-14
IL207182A (en) 2015-06-30
ES2450592T3 (es) 2014-03-25
AU2009209652A1 (en) 2009-08-06
US9180133B2 (en) 2015-11-10
PL2252301T3 (pl) 2014-07-31
EP2252301A1 (en) 2010-11-24
IL234149A0 (en) 2014-09-30
JP2011510949A (ja) 2011-04-07
US20140187525A1 (en) 2014-07-03
US8722653B2 (en) 2014-05-13
AU2009209652B2 (en) 2013-03-21
US20090192130A1 (en) 2009-07-30
JP5906016B2 (ja) 2016-04-20
SI2252301T1 (sl) 2014-05-30
US20160022698A1 (en) 2016-01-28
KR20110021709A (ko) 2011-03-04
CA2713254C (en) 2014-10-07
BRPI0907028A2 (pt) 2015-07-07
KR20150055626A (ko) 2015-05-21
PT2252301E (pt) 2014-02-24
EP2684565A1 (en) 2014-01-15
TW200944211A (en) 2009-11-01
ZA201006049B (en) 2011-05-25
TWI445537B (zh) 2014-07-21
BRPI0907028B8 (pt) 2021-05-25
CY1116485T1 (el) 2017-03-15
BRPI0907028A8 (pt) 2019-08-13
IL234149B (en) 2019-02-28
CA2713254A1 (en) 2009-09-06
HRP20140132T1 (hr) 2014-05-09

Similar Documents

Publication Publication Date Title
DK2252301T3 (en) USE OF ulipristal TREATMENT Uterine Fibroids
JP2011510949A5 (https=)
US20190209562A1 (en) Methods of treating heavy menstrual bleeding
US20070213306A1 (en) Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
US20100021529A1 (en) Step-down estrogen regimen for women receiving estrogen therapy
Garnock-Jones et al. Ulipristal acetate: a review in symptomatic uterine fibroids
JP4883542B2 (ja) エストロゲン化合物とプロゲステロン様化合物よりなるホルモン組成物
TW201400121A (zh) 治療婦科疾病之組合物
JP2019034969A (ja) プロゲステロン受容体アンタゴニスト剤形
WO2011032984A1 (en) Lubiprostone for obstetrical or gynecological applications
US10485808B2 (en) Selective progesterone receptor modulators (SPRM) and stabilized estrogen level in patient
JP2016516764A (ja) 子宮筋腫治療に用いるプロゲステロン受容体調節剤
Barra et al. Vilaprisan. Progesterone receptor modulator, Treatment of uterine fibroids